EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

The journey of canakinumab; on- and off-label indications

Daniela Marotto, Alberto Batticciotto, Angela Ceribelli, Piercarlo Sarzi Puttini

Beyond Rheumatology · 2019

DOI: 10.4081/br.2019.4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Beyond Rheumatology, 2019. Verfasst von Daniela Marotto und 3 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The role of interleukin-1 (IL-1) has been studied in many diseases, ranging from auto-inflammatory diseases to malignancies, and much has been discovered. There are currently four IL-1 inhibitors available, but only two have been approved in Europe: the receptor antagonist anakinra, and the IL-1b selective inhibitor canakinumab. The aim of this paper is to summarise the on- and off-label use of canakinumab (ILARIS®).

Zitieren

APA

Marotto, D., Batticciotto, A., Ceribelli, A., & Puttini, P. S. (2019). The journey of canakinumab; on- and off-label indications. Beyond Rheumatology. https://doi.org/10.4081/br.2019.4

Vancouver

Marotto D, Batticciotto A, Ceribelli A, Puttini PS. The journey of canakinumab; on- and off-label indications. Beyond Rheumatology. 2019. doi:10.4081/br.2019.4

BibTeX
@article{Marotto2019,
  author = {Marotto, Daniela and Batticciotto, Alberto and Ceribelli, Angela and Puttini, Piercarlo Sarzi},
  title = {The journey of canakinumab; on- and off-label indications},
  journal = {Beyond Rheumatology},
  year = {2019},
  doi = {10.4081/br.2019.4}
}
Kostenlos starten →